Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 2, 2012, Pages 509-519

  Zhou, Qingyu ^a   Lv, Hua ^a   Mazloom, Amin R ^a   Xu, Huilei ^a   Ma'ayan, Avi ^a   Gallo, James M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BREAST CANCER RESISTANCE PROTEIN; NEUROGENIN 2; PHOSPHOLIPASE C GAMMA1; PROTEOCHONDROITIN SULFATE; SUNITINIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG PENETRATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE TARGETING; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; GRAFT SURVIVAL; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; MICRODIALYSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PHOSPHOLIPASE C GAMMA; POLYMERASE CHAIN REACTION; PYRROLES;

EID: 84867618631     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.196097     Document Type: Article

References (48)

1. Azam F, Mehta S, and Harris AL (2010) Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 46:1323-1332.
2. Bender C and Ullrich A (2012) PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines. Int J Cancer 131:E45-E55.
3. Bergers G and Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603.
4. Brekke C, Lundervold A, Enger PØ, Brekken C, Stålsett E, Pedersen TB, Haraldseth O, Krüger PG, Bjerkvig R, and Chekenya M (2006) NG2 expression regulates vascular morphology and function in human brain tumours. Neuroimage 29:965-976. (Pubitemid 43121220)
5. Burgess WH, Dionne CA, Kaplow J, Mudd R, Friesel R, Zilberstein A, Schlessinger J, and Jaye M (1990) Characterization and cDNA cloning of phospholipase C-γ, a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase. Mol Cell Biol 10:4770-4777.
6. Casanovas O (2011) The adaptive stroma joining the antiangiogenic resistance front. J Clin Invest 121:1244-1247.
7. Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309. (Pubitemid 41443415)
8. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, and Guillamo JS (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412-423.
9. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, et al. (2010) A combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 10:641.
10. Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, and Chambers TC (2007) Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol 73:481-490. (Pubitemid 46038855)
11. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, and Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239.
12. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, and Stewart CF (2011) Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99.
13. Ferrara N, Hillan KJ, Gerber HP, and Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400. (Pubitemid 38618122)
14. Finke J, Ko J, Rini B, Rayman P, Ireland J, and Cohen P (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 11:856-861.
15. George S (2007) Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep 9:323-327.
16. Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, et al. (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17:7337-7346.
17. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70. (Pubitemid 30046295)
18. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, et al. (2009) Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 64:691-706.
19. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, and Teh BT (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071.
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
21. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989.
22. Kundra V, Escobedo JA, Kazlauskas A, Kim HK, Rhee SG, Williams LT, and Zetter BR (1994) Regulation of chemotaxis by the platelet-derived growth factor receptor-βa. Nature 367:474-476. (Pubitemid 24046051)
23. Kutikov A, Makhov P, Golovine K, Canter DJ, Sirohi M, Street R, Simhan J, Uzzo RG, and Kolenko VM (2011) Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 78:968.e7-11.
24. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309. (Pubitemid 20066716)
25. Liljegren A, Bergh J, and Castany R (2009) Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast 18:259-262.
26. Lucio-Eterovic AK, Piao Y, and de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589-4599.
27. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337. (Pubitemid 36109749)
28. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, and McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000. (Pubitemid 34224587)
29. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524. (Pubitemid 43854967)
30. Nozawa H, Howell G, Suzuki S, Zhang Q, Qi Y, Klein-Seetharaman J, Wells A, Grandis JR, and Thomas SM (2008) Combined inhibition of PLCγ-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 14:4336-4344.
31. Obey TB, Lyle CS, and Chambers TC (2005) Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine. Biochem Biophys Res Commun 335:1179-1184. (Pubitemid 41215542)
32. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, and Geng L (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7:225-233.
33. Ozerdem U, Monosov E, and Stallcup WB (2002) NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res 63:129-134. (Pubitemid 34971515)
34. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, and Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231.
35. Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, and O'Dwyer PJ (2002) Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 63:1699-1707. (Pubitemid 34458009)
36. Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, and Falasca M (2002) The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration. Oncogene 21:6520-6529. (Pubitemid 35155456)
37. Poulin B, Sekiya F, and Rhee SG (2005) Intramolecular interaction between phosphorylated tyrosine-783 and the C-terminal Src homology 2 domain activates phospholipase C-γ1. Proc Natl Acad Sci U S A 102:4276-4781.
38. Shojaei F and Ferrara N (2007) Antiangiogenic therapy for cancer: an update. Cancer J 13:345-348.
39. Shukla S, Robey RW, Bates SE, and Ambudkar SV (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359-365.
40. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, et al. (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46:1116-1119. (Pubitemid 36428215)
41. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, and Schinkel AH (2012) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223-233.
42. Weston CR and Davis RJ (2007) The JNK signal transduction pathway. Curr Opin Cell Biol 19:142-149. (Pubitemid 46386399)
43. Yang J, Ikezoe T, Nishioka C, Takezaki Y, Hanazaki K, Taguchi T, and Yokoyama A (2012) Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer 130:959-966.
44. Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T, and Imamura M (2005) Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 69:159-166. (Pubitemid 41376915)
45. Yu H, Fukami K, Itoh T, and Takenawa T (1998) Phosphorylation of phospholipase Cγ1 on tyrosine residue 783 by platelet-derived growth factor regulates reorganization of the cytoskeleton. Exp Cell Res 243:113-122. (Pubitemid 28397640)
46. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, et al. (2011) Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PloS One 6:e19144.
47. Zhou Q and Gallo JM (2010) Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal 51:958-964.
48. Zhou Q, Guo P, and Gallo JM (2008) Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 14:1540-1549. (Pubitemid 351413939)